Physician profile
Jason Wanner
NPI 1558377713
$2,300.29
in general payments reported to CMS, 2019-2025
22 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $277 · 2021: $197 · 2022: $389 · 2023: $247 · 2024: $443 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $416.51 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| New World Medical,INC. | $270.40 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $263.68 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
| Aerie Pharmaceuticals, INC. | $210.81 | 2019-2021 | |
| Allergan, INC. | $202.75 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $129.66 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $122.17 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $108.04 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $106.21 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $103.69 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $58.38 | 2022-2025 | Oxervate |
| Amgen INC. | $56.95 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $43.14 | 2019-2023 | |
| Ivantis, INC | $36.22 | 2020 | |
| Rayner Intraocular Lenses Limited | $27.97 | 2023 | Rayone Aspheric, Rayone Spheric, Omidria |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $26.84 | 2025 | |
| Kala Pharmaceuticals, INC. | $24.53 | 2021 | |
| Horizon Therapeutics Plc | $22.29 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $20.57 | 2024 | Dextenza |
| Glaukos Corporation | $17.60 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.45 | 2021 | |
| Shire North American Group INC | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.